MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults
The Journals of Gerontology: Series A · 26.01.2023 · 78 (1) · 90-96
DOI: 10.1093/gerona/glac049 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journals of Gerontology: Series A, online erschienen am 01.03.2022. Verfasst von Karol M Pencina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Program in Men's Health: Aging and Metabolism, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: NAD, Nicotinamide Mononucleotide. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Metro International Biotech.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
Nicotinamide adenine dinucleotide (NAD) precursors, nicotinamide mononucleotide (NMN), or nicotinamide riboside (NR) extend healthspan and ameliorate some age-related conditions in model organisms. However, early-phase trials of NAD precursors have yielded varying results and their pharmacokinetics remain incompletely understood. Here, we report the pharmacokinetics and pharmacodynamics of MIB-626, a microcrystalline unique polymorph βNMN formulation.
Methods
In this double-blind, placebo-controlled study, 32 overweight or obese adults, 55–80 years, were block-randomized, stratified by sex, to 1 000-mg MIB-626 once daily, twice daily, or placebo for 14 days. NMN, NAD, and NAD metabolome were measured using liquid chromatography–tandem mass spectrometry.
Results
Participant characteristics were similar across groups. MIB-626 was well tolerated and frequency of adverse events was similar across groups. Blood NMN concentrations on Day 14 in MIB-626-treated groups were significantly higher compared to placebo (1.7-times and 3.7-times increase above baseline in 1 000 mg once-daily and twice-daily groups in mean AUClast, respectively). MIB-626 treatment was associated with substantial dose-related increases in blood NAD levels. Blood levels of NAD metabolites were higher in NMN-treated participants on Days 8 and 14 than at baseline. Changes in NMN or NAD levels were not related to sex, body mass index, or age. Very little unmodified NMN was excreted in the urine.
Conclusion
MIB-626 1 000 mg once-daily or twice-daily regimens were safe and associated with substantial dose-related increases in blood NAD levels and its metabolome. These foundational data that were obtained using a pharmaceutical-grade βNMN, standardized sample collection, and validated liquid chromatography–tandem mass spectrometry assays, should facilitate design of efficacy trials in disease conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Program in Men's Health: Aging and Metabolism, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Metro International Biotech, Worcester, Massachusetts, USA.
ORCID-Profile: Marcello Dos Santos
Förderung
- Metro International Biotech
Zitieren
APA
Pencina, K. M., Lavu, S., Dos Santos, M., Beleva, Y. M., Cheng, M., Livingston, D., & Bhasin, S. (2023). MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The Journals of Gerontology: Series A, 78(1), 90-96. https://doi.org/10.1093/gerona/glac049
Vancouver
Pencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, et al. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The Journals of Gerontology: Series A. 2023;78(1):90-96. doi:10.1093/gerona/glac049
BibTeX
@article{Pencina2023,
author = {Pencina, Karol M and Lavu, Siva and Dos Santos, Marcello and Beleva, Yusnie M and Cheng, Ming and Livingston, David and Bhasin, Shalender},
title = {MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults},
journal = {The Journals of Gerontology: Series A},
year = {2023},
volume = {78},
number = {1},
pages = {90--96},
doi = {10.1093/gerona/glac049}
}
EUVIMED